Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Laryngoscope. 2016 Jul 21;127(4):842–848. doi: 10.1002/lary.26153

Table 2.

Patient characteristics (n = 116)

Variable n (%)pvalue*
Age, mean (range) 56.5 (39-77)ns

Sex Male 94 (81.0)e
Female 22 (19.0)

Primary Site Base of Tongue 71 (61.2)ns
Tonsil 45 (38.8)

Tumor stage T1 28 (24.1)c,e,f,p
T2 47 (40.5)c,e,f,p
T3 30 (25.9)ns
T4 11 (9.5)

Nodal stage N0/1/2a 11 (9.5)ns
N2b 49 (42.2)ns
N2c 43 (37.1)c,e,p
N3 13 (11.2)

HPV/p16 status p16pos &/OR HPVpos 77 (66.4)na
p16neg & HPVneg 1 (0.8)na
P16unknown & HPVneg 9 (7.8)na
P16unknown & HPVunknown 29 (25.0)na

Smoking status Current 25 (21.6)c,e,f,p
Former 35 (30.2)ns
Never 56 (48.3)

Pack years, mean (range) All patients 14.8 (0-132)c,f
p16unknown & HPVunknown 8.1 (0-45)

Treatment Induction + Concurrent/IMRT 46 (39.7)p
Concurrent/IMRT 19 (16.4)ns
Induction + IMRT 51 (44.0)

IMRT Dosing 66Gy 36 (31.0)ns
≥70Gy 80 (69.0)

Post-treatment neck dissection No 93 (80.2)ns
Yes 23 (19.8)

Abbreviations: T, tumor; N, node; HPV, human papillomavirus; IMRT, intensity modulated radiotherapy; Gy, gray.

Superscripts:

*

Univariate longitudinal mixed effects mode with linear spline for MDADI composite and subscale scores, p-value <0.05 is significant; ns, not significant

c

composite p-value<0.05

e

emotional subscale p-value<0.05

f

functional subscale p-value<0.05

p

physical subscale p-value<0.05.